Recruiting NA Paralysis, Unilateral, Vocal Cord

New treatment option for Paralysis, Unilateral, Vocal Cord

Official title APrevent-VOIS-Implant-002 - a Two-Part, Open-Label, Non-Randomized Multicenter Study

ClinicalTrials.gov ID: NCT05119842

What this study is testing

What it's testing
This is a prospective, 2-part, multi-center, open-label, non-randomized clinical trial to assess safety and effectiveness of APrevent® VOIS Implants for the treatment of patients with Unilateral Vocal Fold Paralysis (UVFP). In total 30 evaluable patients are planned to be enrolled.
  • Which group you join is decided by chance.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 to 80. Healthy volunteers may be eligible.

You may be able to join if

  • Male and female patients between 18 and 80 years
  • Diagnosed with permanent UVFP and insufficient glottal closure
  • A significant voice disorder as measured by perceptual rating (Grade ≥2 GRBAS Scale) and Voice Handicap Index (VHI-30 score \>33)
  • Ability to comprehend the full nature and purpose of the study, including possible risks and side effects
  • Ability to co-operate with the Investigator and to comply with the requirements of the entire study

You likely can't join if

  • Any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation...
  • Scheduled elective surgery or other procedures requiring general anaesthesia during clinical investigation
  • Bilateral vocal fold paralysis
  • Had injection medialization laryngoplasty with the injectable still being within the double length of the maximum resorption time frame as stated in...
  • Presence of structural vocal fold lesions such as polyp or nodules
  • Presence of oropharyngeal or laryngeal tumors
See the full eligibility criteria
Who can join
  • Male and female patients between 18 and 80 years
  • Diagnosed with permanent UVFP and insufficient glottal closure
  • A significant voice disorder as measured by perceptual rating (Grade ≥2 GRBAS Scale) and Voice Handicap Index (VHI-30 score \>33)
  • Ability to comprehend the full nature and purpose of the study, including possible risks and side effects
  • Ability to co-operate with the Investigator and to comply with the requirements of the entire study
  • Availability to volunteer for the entire study duration, willing to adhere to all protocol requirements and willing and able to give informed consent for participation
What rules you out
  • Any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the clinical investigation may influence the result of the clinical...
  • Scheduled elective surgery or other procedures requiring general anaesthesia during clinical investigation
  • Bilateral vocal fold paralysis
  • Had injection medialization laryngoplasty with the injectable still being within the double length of the maximum resorption time frame as stated in their approval or as supported by literature.
  • Presence of structural vocal fold lesions such as polyp or nodules
  • Presence of oropharyngeal or laryngeal tumors
  • Patients with diagnosed severe obstructive sleep apnea (OSA)
  • Status post total cordectomy
  • Previous laryngeal framework surgery (any type of thyroplasty, arytenoid adduction)
  • Status post tracheostomy
  • Presence of acute systemic infection at time of screening or shortly before surgery
  • Significant non-laryngeal speech abnormality (severe dysarthria determined by a panel of trained speech therapists)
  • Severe coagulopathy
  • Females who are pregnant, lactating or planning pregnancy are excluded from the investigation
  • Patients with bil. Gr. III-IV hypertrophic tonsils
  • Diabetes mellitus with poor control and poor wound healing history

The study team makes the final eligibility decision.

Where it's taking place

  • Phoenix, Arizona, United States
  • Baltimore, Maryland, United States
  • Cleveland, Ohio, United States
  • Houston, Texas, United States
  • Vienna, Austria
  • Gera, Germany
  • Hamburg, Germany

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years to 80 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Phoenix, Arizona, United States; Baltimore, Maryland, United States; Cleveland, Ohio, United States; Houston, Texas, United States; Vienna, Austria; Gera, Germany and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.